AVBP — Q2 2026 Financial Report Analysis

Overview

ArriVent BioPharma is a clinical-stage drug developer: it has no approved product and no revenue, so its quarterly results are really a record of how much it spends and how long its cash lasts. In the second quarter of 2026 (April–June) it lost $49.9 million, up from $31.4 million a year earlier, as spending on its newer cancer drugs (two antibody-drug conjugates, or ADCs — antibodies that carry a chemotherapy payload directly to tumour cells) more than tripled. It ended June with $373.1 million in cash and short-term investments, after selling $140.0 million of new stock in the first half, and said that was enough to fund operations into 2028.

The quarter has since been overtaken by events. On October 6, 2026 ArriVent announced that FURVENT, the Phase 3 trial of its lead drug firmonertinib in previously untreated lung cancer with EGFR exon 20 insertion mutations, did not meet its primary goal. That was the company's most advanced program, and the result changes how the Q2 numbers below should be read.

At a glance

• Net loss of $49.9 million (-$1.05 per share), up 59% from $31.4 million — the cost of running two Phase 3 trials while pushing two ADCs into human testing.
• $373.1 million in cash and investments, up from $312.8 million at the end of 2025 only because the company sold $140.0 million of stock; without that, it would have been about $233 million.
• FURVENT missed (announced October 6): firmonertinib's 240 mg dose gave a median 11.0 months before the cancer worsened versus 9.5 months on chemotherapy, a gap not large enough to be statistically reliable (p = 0.0654).

Key metrics

Operating margin isn't meaningful for a company with no revenue, and year-over-year percentages on a loss compared with a loss are shown as dollar changes instead.

Where the money went

Research and development rose $14.6 million. The 10-Q breaks it down:

• Early-stage programs: $13.4 million, up from $3.6 million. This is mostly ARR-217, an ADC for gastrointestinal cancers licensed from Lepu Biopharma, which moved into a Phase 1b dose-finding stage, and ARR-002, a two-target ADC for ovarian and endometrial cancer that the FDA cleared for human testing in May 2026.
• Firmonertinib: $17.9 million, up from $16.5 million. Phase 3 trial costs rose $5.0 million to $14.8 million, which the company attributes "primarily" to ALPACCA, its second Phase 3 study (in patients with a different group of uncommon mutations, called PACC). That was partly offset by lower spending on the older FURTHER study and on outside consultants.
• People: $11.0 million, up from $7.6 million, because of more staff.

General and administrative costs rose $4.4 million, which the filing puts down to headcount and consultants. Stock-based pay — compensation in shares rather than cash — doubled to $6.7 million from $3.3 million across the two expense lines.

What the headline numbers hide

• The six-month comparison flatters 2026. Year-to-date, the net loss looks almost flat ($93.2 million vs $95.8 million) and R&D looks lower ($80.0 million vs $89.0 million). That is only because the first half of 2025 included a one-time $40 million upfront payment to Lepu for ARR-217. Excluding it, the first-half 2025 loss would have been about $55.8 million, so the underlying loss has grown by roughly two-thirds.
• Per-share figures understate the growth in losses. The quarterly loss rose 59%, but the loss per share rose only 17%, because the share count grew 36% after the July 2025 public offering and $140.0 million of at-the-market stock sales (5.36 million shares sold gradually into the market) in the first half of 2026. Existing shareholders are funding the growth through dilution, and $229.1 million of capacity remains on that sales program.
• Cash burn is a bit lower than the loss. Operating cash outflow in the first half was $81.5 million against a $93.2 million net loss, mostly because $12.2 million of stock-based pay is a non-cash expense. The remaining difference is small working-capital timing ($0.7 million), so there is no sign of bills being deferred to flatter the burn.
• Interest income is a small cushion. $2.8 million in the quarter from investing the cash pile, up from $2.2 million on larger balances.
• Unrecorded obligations. ArriVent owes Allist (the Chinese company that discovered firmonertinib) up to $765 million in milestone payments and Lepu up to about $1.17 billion; only $11.0 million of development milestones are recorded as payable, because the rest aren't yet probable. A $75 million Silicon Valley Bank loan facility remains undrawn, and $50 million of it depends on meeting conditions and milestones.

The October 6 trial result

FURVENT compared two doses of firmonertinib with standard chemotherapy (platinum plus pemetrexed) in 398 patients. Its main measure was progression-free survival (PFS) — how long patients live without the cancer growing — judged by independent reviewers who didn't know which treatment each patient received.

A hazard ratio below 1 favours the drug; here the 240 mg confidence range reaches 1.02, so the trial can't rule out no benefit. The secondary measures were more encouraging — tumours shrank in 60% of 240 mg patients versus 33% on chemotherapy, investigators saw a longer PFS gap, the company says overall survival is trending in firmonertinib's favour though not yet mature, and serious drug-related side effects were less common than with chemotherapy. But regulators generally weigh the primary endpoint first, and the CEO called the results "disappointing," saying the company is "evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib."

The competitive backdrop makes a path forward harder: the 10-Q notes that amivantamab plus chemotherapy is already approved for first-line exon 20 patients in the US and Europe, and that a first-line application for Dizal's sunvozertinib (now licensed to AstraZeneca) has been submitted to the FDA.

Takeaway: The Q2 numbers show a company spending about $40 million a quarter in cash to fund a late-stage lung cancer bet, paid for by selling shares — and on October 6 the bigger half of that bet, FURVENT, missed its primary endpoint. The $373.1 million cash balance is now the main thing supporting the company's value, and how much of it management commits to firmonertinib versus the ADCs is the decision that matters next.

Outlook

Management's guidance (as of August 12, before the trial result): cash to fund operations into 2028; first patient dosed with ARR-002 in the third quarter; initial ARR-217 dose-escalation data at a future medical conference. The 10-Q itself makes the narrower statement that cash covers at least twelve months from the filing date. ArriVent has not yet said whether the FURVENT miss changes its plans or its runway.

Our read: At the first-half cash-burn pace of roughly $40.7 million a quarter, $373.1 million covers about nine quarters, consistent with "into 2028." That math could move either way. If ArriVent winds down exon 20 work and cuts costs, the runway lengthens; if it keeps funding ALPACCA (which tests the same 240 mg dose in a different mutation group and is ongoing) while scaling two ADC programs, it will likely lean on the ATM again — harder to do on good terms after a trial miss. Things to watch in the Q3 10-Q (expected around mid-November): any restructuring or change in runway guidance, what management decides for ALPACCA, Q3 cash burn, and the size of the upfront payment from Allist under the August 11 ARR-002 China licence (worth up to $80.6 million in total, including milestones), which would be ArriVent's first-ever cash coming in from licensing.